This inventor holds 1 USPTO granted patent. Top assignee: Eli Lilly and Company. Active years: 1990.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1990
Title: Patricia A Reynolds: Innovator in the Field of Biotechnology
Introduction: Patricia A Reynolds, an accomplished inventor based in Indianapolis, IN, has made significant contributions to the field of biotechnology. With her expertise and innovative spirit, she has developed technologies that push the boundaries of genetic research and applications.
Latest Patents: Patricia holds a noteworthy patent titled "Ultrahigh copy number streptomycetes plasmids." This invention discloses a 1.4 kb Bc1I-Sau3A restriction fragment, which contains the minimal replicon of the Streptomyces coelicolor plasmid SCP2*. This innovative minimal replicon is recognized as the smallest self-replicating segment of the SCP2* plasmid, capable of a remarkable increase in plasmid DNA levels—more than a 1000-fold increase compared to the basic replicon. When vectors containing this sequence are transformed into Streptomyces lividans, they enable the construction of smaller and more efficient recombinant DNA shuttle vectors for cloning DNA into streptomycetes.
Career Highlights: Patricia is currently employed at Eli Lilly and Company, where she continues to integrate her research with practical pharmaceutical applications. Her work focuses on enhancing genetic manipulation techniques that are essential in developing new therapeutics.
Collaborations: Throughout her career, Patricia has collaborated with notable colleagues, including Charles L Hershberger and Jeffrey L Larson. These partnerships have been instrumental in advancing her research and enabling innovative solutions within the biotech industry.
Conclusion: Patricia A Reynolds stands out as a pioneering inventor within the biotechnology sector. Her patent for ultrahigh copy number streptomycetes plasmids not only demonstrates her innovative capabilities but also highlights the importance of collaboration in scientific advancement. As she continues her work at Eli Lilly and Company, her contributions are poised to influence future developments in genetic research and its applications for improving human health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile